MiPLA
N-methyl-N-isopropyl-d-lysergamide
Lethal interactions
By drug class
- MAOIslethal2 mechanismsconfidence high
Dangerous interactions
17 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
Cardiovascular
- cardiovascular diseaserelative
Acute cardiovascular stress from sympathomimetic effects. Additional theoretical concern for chronic exposure via 5-HT2B-mediated valve fibrosis (Rouaud et al. 2024). No MiPLA-specific cardiac data.
Neurological
- epilepsyrelative
Seizure threshold reduction is a listed class effect for serotonergic psychedelics. Individuals with epilepsy or other seizure disorders face elevated risk. No MiPLA-specific seizure data exist.
Psychiatric
- psychotic disordersabsolute
All serotonergic psychedelics carry risk of precipitating persistent psychotic states in individuals with vulnerability to psychotic disorders. MiPLA's full substitution for LSD in drug discrimination confirms equivalent 5-HT2A activation.
- bipolar disorderabsolute
Risk of manic episode precipitation. Applies regardless of current mood state or medication status.
Pregnancy & Breastfeeding
- pregnancyabsolute
Contraindicated in pregnancy due to ergoline class uterotonic properties and absence of reproductive safety data. No animal or human reproductive toxicology studies have been conducted for MiPLA.
Other
- lithium co-administrationabsolute
Combination of lithium with LSD-class psychedelics is associated with seizures and severe adverse reactions in community reports and case literature. Absolute contraindication by class.